N/A N=687 Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise
Idiopathic Restless Legs Syndrome
Primary: Severity of Restless Legs Syndrome (RLS) at Bedtime — -2.2; 5.2 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=101 Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
Pulmonary Fibrosis
Primary: Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 52 — -0.5; 4.1 Percentage of predicted FVC — p=0.505
N/A N=311 Non Interventional Study For Patients Treated With Somavert®
Acromegaly
Primary: Serious Adverse Events (SAE) and Adverse Events (AE) — 116; 197 participants
N/A N=344 Non-Interventional Study on the Tolerability and Efficacy of IVIG
Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG
Primary: Adverse Drug Reactions — 17; 37; 0; 1 Participants
N/A N=175 Long-Term Non-Interventional Latanoprost Study
Glaucoma · Ocular Hypertension
Primary: Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent) — 0.25; -0.07; 0.01; 0.04 logMar — p=0.1126
N/A N=220 Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Relapsed Ovarian Cancer
Primary: Progression-Free Survival — 9.46 months
N/A N=4,055 DIA_CENTRAL:T2D Treatment Pattern in Central Europe
Diabetes Mellitus, Type 2
Primary: Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist — 815; 1073; 78…
N/A N=1,313 Patient Convenience Study- NIS RELATE
Atrial Fibrillation
Primary: Mean Perception of Anticoagulant Treatment Questionnaire, Part 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second Assessment Compared to Baseline Assessment — 71.4…
N/A N=171 Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
Non-Interventional Study
Primary: Percentage of Participants With Any Significant Comorbidities — 42.7 percentage of participants
N/A N=692 Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV
Serious Fungal Infections
Primary: Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable — 12.72; 41.47; 17.92; 27.89 percentage of participants
N/A N=1,798 Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Idiopathic Pulmonary Fibrosis
Primary: Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis (IPF) Patients — 781; 202; 190; 255 Participants
N/A N=78 Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
Hemophilia A
Primary: Number of Patients With FVIII Inhibitors — 0; 0; 0 Participants
N/A N=327,624 A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Hospitalization for Heart Failure (HHF), Broad + Specific Definition — 1395; 2043; 765; 1083 Participants — p=<0.005
N/A N=257 OTIVACTO Spain Non Interventional Study
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Patients With Therapeutic Success at Week 6 Approximately (Approx.) (Visit 2) — 66.2 Percentage of Patients (%)
N/A N=108 Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
Age-related Macular Degeneration
Primary: Change From Baseline in Visual Acuity (VA) at Final Visit — 0.61; 0.15 logMAR
N/A N=250 Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
Glabellar Lines
Primary: Percentage of Participants in Each Response Category for Overall Participant Satisfaction at Visit 6, Assessed by the Subject Satisfaction Questionnaire — 71.1; 28.9; 0…
N/A N=28,812 Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — -1.5; -0.7; -1.0; -0.2 mm Hg
N/A N=370 Non-Interventional Study With Aricept® Evess
Alzheimer's Disease · Vascular Dementia
Primary: Change From Baseline in Mini Mental State Examination (MMSE) Total at Week 24 Last Observation Carried Forward (LOCF) — 1.92 Scores on a scale
N/A N=143 LSI (Lesion Index) Workflow Observational Study
Paroxysmal Atrial Fibrillation
Primary: Mean Achieved Lesion Index (LSI) Values — 4.9; 4.8; 4.9; 4.7 Lesion Index
N/A N=2,015 Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
Atrial Fibrillation
Primary: Number of Participants Experiencing Significant Hypotension — 2 Participants
N/A N=2,120 Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment
Atrial Fibrillation
Primary: Creatinine Clearance (Recalculated Using Entries of Age, Gender, Body Weight and Serum Creatinine Made by the Physician) — 55.2 ml/min
N/A N=331 Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Plaque Psoriasis
Primary: Cohort 1: Absolute Psoriasis Area and Severity Index (PASI) Score at Week 48 — 1.13; 1.63 score on a scale
N/A N=186 Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Metastatic Renal Cell Carcinoma
Primary: Percentage of Participants With Objective Response — 25.3 percentage of participants
N/A N=218 A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
Invasive Aspergillosis · Mucormycosis
Primary: Number of Participants With Clinical Response at Week 6 — 173; 14; 27; 3 Participants
N/A N=128 Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Cardiovascular Diseases
Primary: Effectiveness of Niaspan — 41.9755 mg/dL
N/A N=204 OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Idiopathic Pulmonary Fibrosis
Primary: Idiopathic Pulmonary Fibrosis (IPF)-Related Costs — 38923.57; 22613.68; 20369.94; 37183.17 Euro (€) — p=0.0002
N/A N=299 A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Time — 4.87 months
N/A N=65 Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.
HIV Infections
Primary: Adverse Events — 23 Number of patients with adverse events
N/A N=511 NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
Atrial Fibrillation · Paroxysmal Arrhythmia
Primary: Total Fluoroscopy Time — 26.4 minutes
N/A N=10,117 All-Case Surveillance of Ofev in Patients With IPF in Japan
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Any Suspected Adverse Drug Reactions (ADRs) — 3852 Participants